<DOC>
	<DOCNO>NCT02557789</DOCNO>
	<brief_summary>A Phase 1 study assess bioavailability pharmacokinetics 600 mg immediate release tablet formulation lefamulin administer fed fast healthy subject comparison intravenous formulation capsule formulation .</brief_summary>
	<brief_title>Bioavailability Pharmacokinetics Lefamulin When Administered Fed Fasted Healthy Subjects</brief_title>
	<detailed_description>This single center , single cohort , open label , randomize , four- period cross-over study healthy subject receive single dose lefamulin four study session least 4 day apart . Lefamulin take : 1 ) 600 mg IR tablet orally fasted state ; 2 ) 600 mg API capsule ( 3 x 200 mg capsule ) orally fast state ; 3 ) 150 mg i.v . infusion 250 mL citrate buffer saline 1 h ; 4 ) 600 mg IR tablet orally one hour breakfast . The order randomize . A total 20 healthy subject enrol study . The subject take part study session . After study session , Safety Monitoring Team review safety tolerance data commencement subsequent session .</detailed_description>
	<criteria>Healthy subject 1855 year age Good state health ( mentally physically ) determine investigator Body mass index within range 19 32 kg/m2 inclusive A sign date write informed consent form The subject able understand willing comply protocol requirement timetable , instruction protocolstated restriction Any acute chronic illness clinically relevant abnormality identify screen medical assessment , laboratory test ECG ( 12lead Holter ) , unless opinion investigator , consultation Nabriva medical monitor , interfere study procedure , affect outcome study compromise safety subject A known history chronic liver biliary disease , history Gilbert 's syndrome elevate bilirubin level History gastritis , gastrointestinal tract disorder clinical condition previous surgery might affect absorption , distribution , biotransformation , excretion lefamulin Use prescription nonprescription drug within 7 day 10 time elimination halflife ( whichever longer ) prior first dose study medication Any intake prescription nonprescription drug know induce inhibit drugmetabolizing enzyme transport system enzymes within period le 10 time respective elimination halflife , intake grapefruit juice grapefruit containing product within 7 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Absolute bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>